🔄 With new investments, they aim to improve manufacturing efficiency. Collaboration with suppliers is key to enhance the supply chain.
🧬 The demand for lentiviral vectors, especially for CAR-T therapies, fuels this expansion effort.
Introduction:
The article discusses the challenges posed by high manufacturing costs of cell and gene therapies and explores the efforts being made by industry leaders, particularly VIVEbiotech, to lower these costs, thereby increasing patient access and accelerating product development.
- High development and manufacturing costs hinder the accessibility of cell and gene therapies for patients.
- VIVEbiotech aims to enhance production capacity and efficiency through investments and strategic collaborations.
- The use of advanced digital bioprocessing systems is being explored to make manufacturing processes more efficient.
- Collaboration with suppliers is focused on optimizing the supply chain to improve overall operational efficiency.
- There is an increasing demand for lentiviral vectors, particularly for CAR-T therapies, highlighting a promising growth opportunity in the sector.
Conclusion:
By addressing manufacturing inefficiencies and lowering production costs, VIVEbiotech and other stakeholders in the cell and gene therapy space aim to make these vital treatments more accessible to patients while also facilitating faster market entry for new therapies. The ongoing advancements and collaborations signify a collective movement towards optimizing production in this rapidly growing field.
